Agios Pharmaceuticals announced it will not continue developing tebapivat for lower-risk myelodysplastic syndromes (LR-MDS) after its Phase 2b trial failed to meet the predefined efficacy threshold. The 24-week trial involving 65 patients showed tebapivat was well tolerated but did not achieve sufficient clinical benefit in transfusion independence. Despite this, tebapivat remains promising for sickle cell disease, with further Phase 2 data expected later in 2026. This decision reflects the complexity of LR-MDS and challenges in patient response prediction.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
